Medical Management of Diabesity: Do We Have Realistic Targets?
- 687 Downloads
Purpose of Review
The global prevalence of “diabesity”—diabetes related to obesity—is increasing steadily over the past few decades because of the obesity epidemic. Although bariatric surgery is an effective treatment option for patients with diabesity, its limited availability, invasiveness, relatively high costs and the potential for surgical and postsurgical complications restrict its widespread use. Therefore, medical management is the only option for a majority of patients with diabesity. Diabetes control with several anti-diabetic agents, including insulin, causes weight gain with probability of worsening diabesity. Rational use of anti-diabetic medications with weight loss potential in varying combinations may help to address this key issue for long-term management of diabesity. There is no consensus on such an approach from different professional bodies like American Diabetes Association, European Association for Study of Diabetes, or International Diabetes Federation. We attempt to discuss the key issues and realistic targets for diabesity management in this paper.
Rational use of anti-diabetic combinations can mitigate worsening of diabesity to some extent while managing patients.
Retrospective studies showed that combination therapy with glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose co-transporter 2 (SGLT-2) inhibitors, when administered along with other anti-diabetic medications, offer the best therapeutic benefit in the medical management of diabesity. Different combinations of other anti-diabetic drugs with minimum weight gain potential were also found useful. Because of insufficient evidence based on prospective randomised controlled trials (RCTs), future research should focus on evolving the appropriate rational drug combinations for the medical management of diabesity.
KeywordsDiabesity Anti-diabetic medication Anti-diabetic drug combination Anti-obesity agents Management of diabesity
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• World Health Organization. 2015 Obesity and overweight. Geneva: World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/. Assessed 30th March. Data from WHO that gives an idea about the magnitude of the problem.
- 5.• Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73. The first 5-year RCT showing the benefit of bariatric surgery in management of diabesity CrossRefPubMedGoogle Scholar
- 6.• Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR. STAMPEDE investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13. The first well-designed RCT on the benefit of bariatric surgery in diabesity management CrossRefPubMedGoogle Scholar
- 7.• Paulus GF, de Vaan LE, Verdam FJ, Bouvy ND, Ambergen TA, van Heurn LW. Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes Surg. 2015;25:860–78. A recent meta-analysis showing the benefits of gastric bypass procedures CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Chadt A, Scherneck S, Joost HG, Al-Hasani H. 2000-2014. Molecular links between obesity and diabetes: “diabesity”. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.Google Scholar
- 13.Baillot A, Romain AJ, Boisvert-Vigneault K, Audet M, Baillargeon JP, Dionne IJ, Valiquette L, Chakra CN, Avignon A, Langlois MF. Effects of lifestyle interventions that include a physical activity component in class II and III obese individuals: a systematic review and meta-analysis. PLoS One. 2015;10:e0119017.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.•• Franz MJ, Boucher JL, Rutten-Ramos S, Van Wormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447–63. A study of different RCTs on the management of diabesity through weight loss by lifestyle changes CrossRefPubMedGoogle Scholar
- 20.•• Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–70. An important study showing the effects of different drugs on body weight CrossRefPubMedGoogle Scholar
- 26.•• Jiang YF, Chen XY, Ding T, Wang XF, Zhu ZN, Su SW. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2015;100:2071–80. A study on the role of metformin for gestational diabetes CrossRefPubMedGoogle Scholar
- 27.• Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. A clinical practice guideline helping physicians to manage NAFLD appropriately] CrossRefPubMedGoogle Scholar
- 33.•• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. A recent clinical trial showing the cardiovascular mortality benefit of GLP-1 receptor agonists CrossRefPubMedPubMedCentralGoogle Scholar
- 38.• Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366. A meta-analysis that refuted the scare about the elevated pancreatitis risk associated with GLP-1 receptor agonists CrossRefPubMedPubMedCentralGoogle Scholar
- 44.•• Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610. A systematic review compiling evidence for increased risk of hospitalization among patients treated with DPP-4 inhibitors CrossRefPubMedPubMedCentralGoogle Scholar
- 45.•• Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74. Article showing efficacy of different SGLT-2 inhibitors in the management of diabesity. CrossRefPubMedGoogle Scholar
- 48.•• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. The first clinical trial showing cardiovascular mortality benefit and weight loss effect of an antidiabetic medication CrossRefPubMedGoogle Scholar
- 52.Plock N, Bax L, Lee D, DeManno D, Lahu G, Pfister M. Exploratory literature meta-analysis to characterize the relationship between early and longer term body weight loss for antiobesity compounds. J Clin Pharmacol. 2017;57:52–63.Google Scholar
- 54.• Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab. 2012;97:4682–91. An article looking at pancreatic glucotoxicity and its effects on diabetes control CrossRefPubMedGoogle Scholar
- 61.Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, et al. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen insulin and metformin therapy (CIMT) trial. BMJ Open. 2016;6:e008376.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Zhang F, Xiang H, Fan Y, Ganchuluun TA, Kong W, Ouyang Q, Sun J, Cao B, Jiang H, Nie S. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2013;44:648–58.CrossRefPubMedGoogle Scholar
- 64.•• Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Clinical guidelines Committee of the American College of physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156:756. An article looking at different combination regimens for appropriate management of T2 DM CrossRefGoogle Scholar
- 65.Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y, Zaccaro E, Coleman CI. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10:e0125879.CrossRefPubMedPubMedCentralGoogle Scholar
- 66.Zhong X, Zhang T, Liu Y, Wei X, Zhang X, Qin Y, Jin Z, Chen Q, Ma X, Wang R, He J. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes sub-optimally controlled with metformin and/or a sulfonylurea: a network meta-analysis. Diabetes Res Clin Pract. 2015;109:451–60.CrossRefPubMedGoogle Scholar
- 69.Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open. 2014;4:e005442.CrossRefPubMedPubMedCentralGoogle Scholar
- 72.• Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–51. An important article looking at evidence base for rational antidiabetic combinations CrossRefPubMedGoogle Scholar
- 74.• Kawalec P, Mikrut A, Łopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30:269–83. An article showing benefit of combination of DPP-4 inhibitors and SGLT-2 inhibitors in the management of diabesity Google Scholar
- 75.• Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, Sihabout A, Salamucha I, Coleman CI. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med. 2015;32:1530–40. An article that shows beneficial effect of adding an SGLT-2 inhibitor to other antidiabetic agents in managing diabesity CrossRefPubMedGoogle Scholar
- 77.Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in The management of T2DM. Endocr Pract. 2015;21:1315–22. A retrospective study showing the benefit of add on therapy of SGLT-2 inhibitors with GLP-1 receptor agonists in patients with diabesity CrossRefPubMedGoogle Scholar
- 78.•• Deol H, Lekkakou L, Viswanath AK, Pappachan JM. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors for the management of diabesity: the real world experience. Endocrine. 2017;55:173–8. A retrospective study showing remarkable benefit of adding an SGLT-2 inhibitor to GLP-1 receptor agonist in the medical management of diabesity CrossRefPubMedGoogle Scholar